- Home
- CLLS vs GOSS Comparison
CLLS vs GOSS Comparison
Compare CLLS & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- GOSS
- Stock Information
- Founded
- CLLS 1999
- GOSS 2015
- Country
- CLLS France
- GOSS United States
- Employees
- CLLS N/A
- GOSS N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- GOSS Health Care
- Exchange
- CLLS Nasdaq
- GOSS Nasdaq
- Market Cap
- CLLS 143.4M
- GOSS 262.5M
- IPO Year
- CLLS 2007
- GOSS 2019
- Fundamental
- Price
- CLLS $1.65
- GOSS $1.21
- Analyst Decision
- CLLS Buy
- GOSS Strong Buy
- Analyst Count
- CLLS 1
- GOSS 3
- Target Price
- CLLS $4.00
- GOSS $7.33
- AVG Volume (30 Days)
- CLLS 52.9K
- GOSS 2.6M
- Earning Date
- CLLS 08-05-2025
- GOSS 08-11-2025
- Dividend Yield
- CLLS N/A
- GOSS N/A
- EPS Growth
- CLLS N/A
- GOSS N/A
- EPS
- CLLS N/A
- GOSS N/A
- Revenue
- CLLS $54,747,000.00
- GOSS $124,590,000.00
- Revenue This Year
- CLLS $48.52
- GOSS N/A
- Revenue Next Year
- CLLS $5.17
- GOSS $91.14
- P/E Ratio
- CLLS N/A
- GOSS N/A
- Revenue Growth
- CLLS 351.26
- GOSS N/A
- 52 Week Low
- CLLS $1.10
- GOSS $0.66
- 52 Week High
- CLLS $2.43
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- CLLS 66.75
- GOSS 46.78
- Support Level
- CLLS $1.41
- GOSS $1.20
- Resistance Level
- CLLS $1.49
- GOSS $1.33
- Average True Range (ATR)
- CLLS 0.10
- GOSS 0.10
- MACD
- CLLS 0.02
- GOSS -0.02
- Stochastic Oscillator
- CLLS 98.45
- GOSS 6.12
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.